Mohamad Mohty, Head of the Clinical Hematology and Cellular Therapy Department at Saint-Antoine Hospital, Sorbonne University, shared a post on X:
“Congratulations to the PARADIGM team!
Aza-Ven delivering longer EFS, better responses, smoother journeys to transplant… the data are speaking loudly. Maybe it is finally time to let conventional induction chemotherapy enjoy a well-deserved retirement.”
More posts featuring Mohamad Mohty.
